Lukowsky Ansgar, Marchwat Maren, Sterry Wolfram, Gellrich Sylke
Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany.
Leuk Lymphoma. 2006 Mar;47(3):487-93. doi: 10.1080/10428190500305380.
Polymerase chain reaction (PCR)-based detection of clonal T- and B-cells is widely used in the diagnosis of various lymphomas, including those of the skin. A large number of corresponding methods have been published. Recently, for the first time, standardized PCR protocols were developed in common by 14 European centers of lymphoma diagnosis and research (Biomed-2 protocols). Here, we have applied Biomed-2 immunoglobulin heavy chain (IgH)-PCR for clonality detection in primary cutaneous B-cell lymphoma (CBCL) and compared it with previously established methods. The DNA of 43 paraffin-embedded lesional skin biopsies of confirmed CBCL cases [27 follicle center cell lymphoma (FCCL), 11 marginal zone B-cell lymphoma/immunocytoma (MZL/IC) and five large CBCL of the lower leg (CBCL-LL)] were amplified by the Biomed-2 IgH-PCR protocols as well as using four other assays, priming also the three IgH framework regions (FR) 1-3. All PCR products were analysed by fluorescence fragment analysis. Twenty-nine of 43 (67%) CBCL samples (5/5, 100% of CBCL-LL; six of 11, 54.5% of IC/MZL; 18 of 27, 66.7% of FCCL) showed monoclonal B-cell presence complementary in all of the IgH-PCR. The three Biomed-2 PCR indicated together clonality in 24 of 43 samples (56%). Considering each method separately, the Biomed-2 FR3-PCR showed the highest rate of clonality detection (20 of 43, 47%). In conclusion, the Biomed-2 FR3-PCR is recommended for detecting B-cell clonality in archival skin samples of CBCL but should be completed by FR1- and/or FR2-PCR.
基于聚合酶链反应(PCR)检测克隆性T细胞和B细胞在包括皮肤淋巴瘤在内的各种淋巴瘤诊断中广泛应用。大量相应方法已被发表。最近,14个欧洲淋巴瘤诊断与研究中心首次共同制定了标准化的PCR方案(Biomed-2方案)。在此,我们应用Biomed-2免疫球蛋白重链(IgH)-PCR检测原发性皮肤B细胞淋巴瘤(CBCL)的克隆性,并将其与先前建立的方法进行比较。采用Biomed-2 IgH-PCR方案以及其他四种检测方法,对43例确诊的CBCL病例(27例滤泡中心细胞淋巴瘤(FCCL)、11例边缘区B细胞淋巴瘤/免疫细胞瘤(MZL/IC)和5例小腿大细胞CBCL(CBCL-LL))石蜡包埋的病变皮肤活检组织DNA进行扩增,引物也针对免疫球蛋白重链的三个框架区(FR)1-3。所有PCR产物通过荧光片段分析进行检测。43例CBCL样本中有29例(67%)(5/5,CBCL-LL的100%;11例中的6例,IC/MZL的54.5%;27例中的18例,FCCL的66.7%)在所有IgH-PCR中均显示单克隆B细胞存在。三种Biomed-2 PCR共同显示43例样本中有24例(56%)存在克隆性。单独考虑每种方法,Biomed-2 FR3-PCR显示克隆性检测率最高(43例中的20例,47%)。总之,推荐使用Biomed-2 FR3-PCR检测CBCL存档皮肤样本中的B细胞克隆性,但应通过FR1和/或FR2-PCR进行补充。